Skip to main content
. Author manuscript; available in PMC: 2020 Dec 1.
Published in final edited form as: Clin Cancer Res. 2020 Jan 7;26(11):2654–2663. doi: 10.1158/1078-0432.CCR-19-3563

Figure 4. The genomic profile and clinical outcomes of patient with histologic transformation.

Figure 4.

A, Genomic patterns pre- and post-osimertinib by histologic transformation subtype. Green shaded rectangle represents mutation. Blue shaded rectangle represents copy number gain. Red shaded rectangle represents deletion. B, Pre-treatment biopsy shows adenocarcinoma, which is positive for TTF-1 and negative for p40 by immunohistochemistry. Post-treatment sample show squamous cell carcinoma, which is negative for TTF-1 and positive for p40 by immunohistochemistry. C, Treatment regimens received by patients with histologic transformation and overall survival after osimertinib.